Stallergenes Greer, Shionogi & Co., Ltd. ("Shionogi") and CEOLIA Pharma Co. Ltd ("CEOLIA") today announced the transition of promotional activities for Actair® in Japan. Actair® is Stallergenes ...

Swiss waters have warmed up considerably due to the hot weather. Over the last two weeks, lake temperatures have risen by an ...

Some 9,196 recreational athletes swam across Lake Zurich on Wednesday in waters measuring 27 degrees Celcius. The event was ...

BioVersys & Shionogi ink global research collaboration for broad-spectrum NTM clinical candidate: Basel, Switzerland Thursday, July 3, 2025, 10:00 Hrs [IST] BioVersys AG, a multi- ...

The global house dust mite allergy treatment market size was US$ 1.5 billion in 2021. The global house dust mite allergy treatment market size is forecast to reach US$ 4.6 billion by 2030, growing at ...

There will be another ‘COVID’. Governments are planning for it, but how coordinated is that planning, and how resilient will ...

Antibiotics specialist Bioversys AG has sealed a potential CHF529 million (US$667.5 million) deal with Shionogi Co. Ltd., in which they will work together on novel ansamycins for treating ...

Shionogi will pay BioVersys $6.3 million for developing BV500, BioVersys's drug candidate for non-tuberculous mycobacteria.

Swiss biopharma company BioVersys (today announced a research and exclusive license option agreement with the Japanese ...

AN Venture Partners has closed its first fund, a $200 million vault for biotechs worldwide, with particular emphasis on ...

BASEL, Switzerland I July 02, 2025 I BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of ...

Basel-based BioVersys stands to receive CHF 5 million upfront under the terms of the deal, which could be worth up to CHF 479 ...